Advertising Claims for Parent’s Choice Probiotic Colic Drops Discontinued Following Challenge by Nestle Nutrition

New York, NY – Feb. 15, 2019 – BioAmicus Laboratories, Inc. has agreed to permanently discontinue certain challenged advertising claims for its Parent’s Choice Probiotic Colic Drops product, including claims that the drops are “Clinically shown to reduce crying time by 50%”  following a challenged filed with the National Advertising Division by Nestle Nutrition, maker of Gerber Soothe Probiotic Drops.

NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.

The challenged claims, which appeared on the product’s packaging, included:

  • “Compare To Gerber Soothe Probiotic Colic Drops.”
  • “For excessive crying & colic. Clinically shown to reduce crying time.”
  • “Clinically shown to reduce crying time by 50%.”
  • “Probiotic L. reuteri helps to promote a healthy balance of beneficial bacteria in baby’s digestive comfort.”

During the course of NAD’s review, BioAmicus Laboratories agreed in writing to permanently discontinue each of the challenged claims. In reliance on the advertiser’s written representation that the claims will be permanently discontinued, NAD did not review the claims on their merits. The voluntarily discontinued claims will be treated, for compliance purposes, as though NAD recommended their discontinuance and the advertiser agreed to comply.

In its advertiser’s statement, BioAmicus Laboratories reiterated that it and its partners agree to voluntarily and permanently discontinue the above mentioned claims and to not produce any new packaging containing these statements.”

Note: A recommendation by NAD to modify or discontinue a claim is not a finding of wrongdoing and an advertiser’s voluntary discontinuance or modification of claims should not be construed as an admission of impropriety. It is the policy of NAD not to endorse any company, product, or service. Decisions finding that advertising claims have been substantiated should not be construed as endorsements.

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Blueprint Test Preparation Discontinue Certain MCAT Score Improvement Claims

New York, NY – April 22, 2024 – The National Advertising Division recommended Blueprint Test Preparation discontinue certain express and implied claims made in connection with its four MCAT preparation courses, including claims that Blueprint students raise their MCAT scores by 15 or 13 points on average.

Read the Decision Summary
Decision

National Advertising Division Recommends The Princeton Review Discontinue Point Increase Claims for MCAT Test Preparation Services

New York, NY – April 18, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division recommended that The Princeton Review (TPR) discontinue claims that its students “Score a 515+ on the MCAT or add 15 points depending on your starting score. Guaranteed or your money back.”

Read the Decision Summary
Decision

Direct Selling Self-Regulatory Council Recommends Trades of Hope Discontinue Salesforce Member Earnings Claims

McLean, VA – April 17, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) recommended that Trades of Hope discontinue certain earnings claims made by salesforce members on Facebook and YouTube. 

Read the Decision Summary
Decision

National Advertising Division Recommends Lily of the Desert Nutraceuticals Discontinue “100% Pure Avocado Oil” Claim for Tropical Plantation Avocado Oil

New York, NY – April 15, 2024 – The National Advertising Division recommended that Lily of the Desert Nutraceuticals discontinue the claim “100% Pure Avocado Oil” for its Tropical Plantation Avocado Oil and avoid conveying the unsupported message that the product is 100% pure avocado...

Read the Decision Summary